In assessing the current market environment, the author of today’s article notes that “it becomes apparent that there’s an opportunity for those able to take on more risk. Within the biotech space, the effects of COVID-19 have pushed several compelling names’ share prices lower, presenting more affordable entry points.” For three of these compelling biotech stocks – all of which are trading under $4, are Buy-rated, and possess significant upside potential in the next year – CLICK HERE.